Skip to content
CompletedPhase 2Results posted

A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms

NCT05407064 · Definium Therapeutics US, Inc.

Closed to entry
Status
Not accepting participants
Phase 2
Phase
198
Target enrolment
22
Study sites
13 US states

What it is testing

Summary

This is a Phase 2, multi-center, randomized, double-blind, parallel-group, dose-finding study to assess the effect of 4 doses of MM120 (25, 50, 100 or 200 μg freebase-equivalent) for the treatment of anxiety symptoms in subjects diagnosed with generalized anxiety disorder (GAD).

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Dose Response

    Measured over 4 weeks

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 74 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: * Bodyweight of ≥ 50 kg * Body mass index \[BMI\] ≥ 18 to ≤ 38 mg/kg2 * Diagnosis of DSM-5 generalized anxiety disorder * Acceptable overall medical condition to be safely enrolled into and to complete the study * Ability to swallow capsules * Ability to provide informed consent Exclusion Criteria: * Women of childbearing potential (WOCBP) (i.e., physiologically capable of becoming pregnant) who are unwilling or unable to use a highly effective method of contraception for the duration of the study, OR Men physiologically capable of fathering a child who are sexually active with WOCBP but are unwilling or unable to use barrier contraception (e.g., condom with or without spermicidal cream or jelly) for the duration of the study * Women who are currently pregnant or breastfeeding or plan to become pregnant or breastfeed during the study * Men who plan to donate sperm during the study * Prior history (lifetime diagnosis) with a lifetime diagnosis of schizophrenia spectrum, or other psychotic disorders or bipolar disorder * Has a significant risk of suicide attempt based upon medical history or has active suicidal ideation * Unwillingness or inability to discontinue prohibited concomitant medications, supplements or other therapeutics (prescription or over-the-counter)

Where

22 study sites

FacilityCityRegionCountry
Preferred Research PartnersLittle RockArkansasUnited States
Irvine Center for Clinical ResearchIrvineCaliforniaUnited States
Kadima Neuropsychiatry InstituteLa JollaCaliforniaUnited States
Pacific Neuroscience InstituteSanta MonicaCaliforniaUnited States
Mountain View Clinical ResearchDenverColoradoUnited States
Wholeness CenterFort CollinsColoradoUnited States
Segal TrialsLauderhillFloridaUnited States
CNS Healthcare - OrlandoOrlandoFloridaUnited States
iResearch AtlantaDecaturGeorgiaUnited States
Great Lakes Clinical TrialsChicagoIllinoisUnited States
Uptown ResearchChicagoIllinoisUnited States
Sunstone TherapiesRockvilleMarylandUnited States
SISUSpringfieldMassachusettsUnited States
Adams ClinicalWatertownMassachusettsUnited States
Hassman Research InstituteBerlinNew JerseyUnited States
GMI - Princeton Medical InstitutePrincetonNew JerseyUnited States
Lutheran Hospital - Cleveland ClinicClevelandOhioUnited States
BioBehavioral Research of AustinAustinTexasUnited States
University of Texas Health HoustonHoustonTexasUnited States
Cedar Clinical ResearchDraperUtahUnited States
Cedar Clinical Research - MurrayMurrayUtahUnited States
Woodstock Research CenterWoodstockVermontUnited States

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT05407064 on ClinicalTrials.gov →

Last updated in the registry 2026-02-27. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits